UK markets closed
NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,475.92 +268.82 (+1.48%) CRUDE OIL
78.54 +0.43 (+0.55%) GOLD FUTURES
2,310.60 +2.00 (+0.09%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
50,888.97 +179.19 (+0.35%)
Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 3.55B |
| Enterprise value | 3.02B |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 7.24 |
| Price/book (mrq) | 12.90 |
| Enterprise value/revenue | 6.95 |
| Enterprise value/EBITDA | -5.85 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.66 |
| 52-week change 3 | -8.18% |
| S&P500 52-week change 3 | 22.38% |
| 52-week high 3 | 54.98 |
| 52-week low 3 | 31.52 |
| 50-day moving average 3 | 47.43 |
| 200-day moving average 3 | 42.11 |
Share statistics
| Avg vol (3-month) 3 | 717.59k |
| Avg vol (10-day) 3 | 745.24k |
| Shares outstanding 5 | 83.13M |
| Implied shares outstanding 6 | 83.13M |
| Float 8 | 72.91M |
| % held by insiders 1 | 4.02% |
| % held by institutions 1 | 100.16% |
| Shares short (15 Apr 2024) 4 | 4.38M |
| Short ratio (15 Apr 2024) 4 | 6.09 |
| Short % of float (15 Apr 2024) 4 | 6.15% |
| Short % of shares outstanding (15 Apr 2024) 4 | 5.27% |
| Shares short (prior month 15 Mar 2024) 4 | 3.78M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | -138.58% |
| Operating margin (ttm) | -151.93% |
Management effectiveness
| Return on assets (ttm) | -26.97% |
| Return on equity (ttm) | -340.05% |
Income statement
| Revenue (ttm) | 442.59M |
| Revenue per share (ttm) | 5.75 |
| Quarterly revenue growth (yoy) | 8.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -550.84M |
| Net income avi to common (ttm) | -613.35M |
| Diluted EPS (ttm) | -8.25 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 412.08M |
| Total cash per share (mrq) | 4.96 |
| Total debt (mrq) | 932.17M |
| Total debt/equity (mrq) | 664.59% |
| Current ratio (mrq) | 2.43 |
| Book value per share (mrq) | 1.69 |
Cash flow statement
| Operating cash flow (ttm) | -508.67M |
| Levered free cash flow (ttm) | -329.48M |
© 2024 Yahoo. All rights reserved.